Evaluation of Peripheral Blood Protein Biomarkers for Colorectal Cancer Screening

University Hospital, Rouen3 个研究点分布在 1 个国家目标入组 350 人2022年12月9日

适应症Colorectal Cancer

干预措施blood sampling for screening of biomarkers

概览

阶段: 不适用
干预措施: blood sampling for screening of biomarkers
疾病 / 适应症: Colorectal Cancer
发起方: University Hospital, Rouen
入组人数: 350
试验地点: 3
主要终点: Number of patient with advanced neoplasia at colonoscopy
状态: 已完成
最后更新: 2个月前

概览研究者入排标准研究组 & 干预措施结局指标研究点相似试验

概览

简要总结

The aim of the study is to validate the value of value of peripheral blood protein biomarkers in colorectal cancer screening, and to identify new ones

注册库

clinicaltrials.gov

开始日期

2022年12月9日

结束日期

2024年9月26日

最后更新

2个月前

研究类型

Interventional

研究设计

Single Group

性别

All

研究者

发起方

University Hospital, Rouen

责任方

Sponsor

入排标准

入选标准

•Patient aged 50 years or older referred for screening colonoscopy after a positive FIT test or for endoscopic resection of a previously identified suspicious colorectal lesion

排除标准

•Very high risk of colorectal cancer: Lynch syndrome, Familial adenomatous polyposis, Peutz-Jeghers syndrome, Familial polyposis associated with a MutYH gene defect
•Other solid cancers or haematological malignancies that are progressive and/or undergoing treatment (apart from basal cell skin carcinoma)
•Contraindication to total colonoscopy

研究组 & 干预措施

Patient referred for screening colonoscopy or for endoscopic resection

Patient aged 50 years or older referred for screening colonoscopy after a positive fecal immunochemical test or for endoscopic resection of a previously identified suspicious colorectal lesion will have a blood sampling for biomarkers detection

干预措施: blood sampling for screening of biomarkers